

GPRA 2015

Immunization Measures

Amy V. Groom, MPH

IHS Immunization Program Manager

GPRRA/GPRAMA Immunization Measures

- Childhood Immunizations
 - 4313314 coverage among children 19-35 months
 - Updated codes for FY 2015
 - Target: 73.9%
- Adult Immunizations
 - Pneumococcal vaccination among adults 65 years+
 - Pneumo vaccination on or after age 65 years (changed in FY 2014)
 - Updated codes for FY 2015
 - Target: 85.7%
 - Influenza vaccination among adults 65 years+
 - Updated codes for FY 2015
 - Target: 67.2%

Developmental Measures

- Adult Composite measure
 - Looks at age-appropriate coverage among adults 19 years and older
 - FY 2014 results: 32.9% of adults 19 years and older received all recommended vaccines

Age Groups	Recommended Vaccines	Composite Measure Vaccines
19-59 years	Td in last 10 years, Tdap and Influenza	Td/Tdap, Tdap ever, and Influenza
60-64 years	Td in last 10 years, Tdap, Influenza ,and Zoster	Td/Tdap, Tdap ever, Influenza ,and Zoster
65 years and older	Td in last 10 years, Tdap, Influenza, Zoster, and Pneumococcal Polysaccharide Vaccine, 23 Valent (PPSV23)	Td/Tdap, Tdap ever, Influenza, Zoster, and Pneumococcal Polysaccharide Vaccine, 23 Valent (PPSV23)
All Ages	All age-appropriate vaccines	Proportion of adults who received all vaccines recommended for their age group

- Pneumococcal vaccine for adults 65+ years
 - Developmental measure to exclude pneumococcal conjugate vaccine codes for this measure
- Childhood 4313313 measure
 - Looks at 3 pneumococcal conjugate rather than 4
 - Developed in the event ACIP decides to routinely recommend 3 rather than 4 doses of PCV13. No decision has yet been made.

The PCV13 Conundrum

- 23-valent Pneumococcal Polysaccharide Vaccine (PPSV23) is currently recommended for all adults 65 years and older
- In August 2014, the Advisory Committee on Immunization Practices voted to ALSO routinely recommend the 13-valent pneumococcal conjugate vaccine (PCV13) for ALL adults 65 years and older
- TIME LIMITED recommendation
 - To be re-visited in 2018

Issues

- Adults 65 years and older recommended to receive BOTH PCV13 and PPSV23
- In patients not previously vaccinated with PPSV23
 - Should receive PCV13 first
 - Recommended interval between PCV13 and PPSV23 is 6 months to 1 year
- Patients who have received PPSV23 on or after age 65 years
 - Should receive dose of PCV13 at least 1 year after PPSV23

PCV13 – Impact on current GPRA Measure

- Current GPRA Pneumococcal logic counts PCV13 as a dose of PPSV23 for the purposes of the GPRA Pneumococcal measure
 - Prior to the 2014 PCV13 recommendation, these likely represented miscodes for PPSV23
 - With new recommendation, more adults likely to receive PCV13
 - Inclusion of PCV13 codes may result in over-estimate of true PPSV23 coverage
 - Exclusion of PCV13 codes would, however, unfairly “ding” sites who follow the recommendation, as there is a 6 – 12 month recommended interval required between PCV13 and PPSV23

GPRA Pneumococcal Logic

- Because PCV13 for adults 65 years and older is a time-limited recommendation, we will NOT update current GPRA logic to reflect changes
- GPRA logic will continue to count PCV13 codes as valid for meeting the PPSV23 requirement
- This may result in an over-estimate of current PPSV23 coverage